Business Context and Reporting Period
This Form 8-K was filed by Neuralstem, Inc. (not Palisade Bio, Inc.) on February 15, 2011. The report discloses a corporate governance change involving the expansion of the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial statements.
Material Changes
- Board Expansion: The Board of Directors increased the number of directors from four to five.
- New Appointment: Mr. Stanley Westreich was appointed as a Class II director, serving until the 2013 annual shareholders meeting or until resignation/removal.
- Compensation: Mr. Westreich will be compensated under the Company's non-executive board compensation policy.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on operations, or discussion of risks and contingencies. The document is limited to the announcement of the director appointment and the attachment of a press release (Exhibit 99.01).
Investor Verification Checklist
- Verify the full text of the press release attached as Exhibit 99.01 for additional context on the appointment.
- Review the Company's non-executive board compensation policy to understand the specific financial terms of Mr. Westreich's appointment.
- Confirm the current composition of the Board of Directors following this expansion.
- Note the discrepancy between the requested company name (Palisade Bio, Inc.) and the actual registrant (Neuralstem, Inc.).